Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 00370M103 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
TCG Crossover GP I, LLC
13G/A
|
7.0% |
8/14/2026
Event 6/30/2026
|
||
| TCG Crossover GP I, LLC | 5.7% | |||
| TCG Crossover Fund I, L.P. | 5.7% | |||
| TCG Crossover GP II, LLC | 1.3% | |||
| TCG Crossover Fund II, L.P. | 1.3% | |||
| Chen Yu | 7.0% | |||
|
Invus Global Management, LLC
13G/A
|
6.0% |
8/13/2026
Event 6/30/2026
|
||
| Invus Public Equities, L.P. | 6.0% | |||
| Invus Public Equities Advisors, LLC | 6.0% | |||
| Invus Global Management, LLC | 6.0% | |||
| Siren, L.L.C. | 6.0% | |||
| Avicenna Life Sci Master Fund LP | 0% | |||
| Avicenna Life Sci Master GP LLC | 0% | |||
| Ulys, L.L.C. | 0% | |||
| Raymond Debbane | 6.0% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Deep Track Capital, LP
13G/A
|
4.8% |
8/14/2025
Event 6/30/2025
|
||
| Deep Track Capital, LP | 4.8% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 4.8% | |||
| David Kroin | 4.8% | |||
|
Sofinnova Crossover I
13D/A
|
4.3% |
7/6/2026
Event 7/2/2026
|
||
| Sofinnova Crossover I SLP | 4.3% | |||
| Sofinnova Partners SAS | 4.3% | |||
| Antoine Papiernik | 4.3% | |||
| Cedric Moreau | 4.3% | |||
| Kinam Hong | 4.3% | |||
| Joseph Anderson | 4.3% | |||
| Jacques Theurillat | 4.3% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
0.8% |
11/14/2025
Event 9/30/2025
|
||
| Venrock Healthcare Capital Partners III, L.P. | 0.8% | |||
| VHCP Co-Investment Holdings III, LLC | 0.8% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 0.8% | |||
| VHCP Management III, LLC | 0.8% | |||
| VHCP Management EG, LLC | 0.8% | |||
| Nimish Shah | 0.8% | |||
| Bong Y. Koh | 0.8% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 9 | 700 k | $69.3 M |
| 2026 Q2 | 370 | 55.1 M | $7.20 B |
| 2026 Q1 | 291 | 50.4 M | $5.57 B |
| 2025 Q4 | 278 | 56.3 M | $7.61 B |
| 2025 Q3 | 171 | 52.1 M | $4.42 B |
| 2025 Q2 | 44 | 30.7 M | $235 M |
| 2025 Q1 | 47 | 31.8 M | $199 M |
| 2024 Q4 | 49 | 29.9 M | $219 M |
| 2024 Q3 | 41 | 27.4 M | $313 M |
| 2024 Q2 | 41 | 29.6 M | $392 M |
| 2024 Q1 | 39 | 24.6 M | $351 M |
| 2023 Q4 | 33 | 22.7 M | $243 M |